Correction to: Cost-Effectiveness, Burden of Disease and Budget Impact of Inclisiran: Dynamic Cohort Modelling of a Real-World Population with Cardiovascular Disease.

Galactionova, Katya; Salari, Paola; Mattli, Renato; Rachamin, Yael; Meier, Rahel; Schwenkglenks, Matthias

Galactionova, Katya; Salari, Paola; Mattli, Renato; Rachamin, Yael; Meier, Rahel; Schwenkglenks, Matthias.

Afiliación

Galactionova K; Institute of Pharmaceutical Medicine (ECPM), University of Basel, Basel, Switzerland.
Salari P; Institute of Pharmaceutical Medicine (ECPM), University of Basel, Basel, Switzerland.
Mattli R; Winterthur Institute of Health Economics, Zurich University of Applied Sciences, Winterthur, Switzerland.
Rachamin Y; Institute of Primary Care, University of Zurich, Zurich, Switzerland.
Meier R; University Hospital Zurich, Zurich, Switzerland.
Schwenkglenks M; Institute of Primary Care, University of Zurich, Zurich, Switzerland.

Pharmacoeconomics ; 40(8): 835, 2022 Aug.

Article en En | MEDLINE | ID: mdl-35798916

Texto completo

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Tipo de estudio: Health_economic_evaluation Idioma: En Revista: Pharmacoeconomics Asunto de la revista: FARMACOLOGIA / TERAPIA POR MEDICAMENTOS Año: 2022 Tipo del documento: Article País de afiliación: Suiza

Texto completo

Imprimir

XML

PubMed Links

Buscar en Google